KK
AKBA icon

KLP Kapitalforvaltning’s Akebia Therapeutics AKBA Stock Holding History

KLP Kapitalforvaltning’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-54,800
Closed -$88.2K – 2155
2025
Q4 		$88.2K Hold
54,800
– – ﹤0.01% 2101
2025
Q3 		$150K Buy
+54,800
New +$182K ﹤0.01% 1922

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

KLP Kapitalforvaltning's AKBA Position: Q1 2026 in Review

KLP Kapitalforvaltning sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 54,800 shares — an estimated $88.2K sold.

KLP Kapitalforvaltning first reported a position in AKBA in Q3 2025 and held it in 2 quarters. The position peaked at $150K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • KLP Kapitalforvaltning reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • KLP Kapitalforvaltning sold 54,800 Akebia Therapeutics shares in Q1 2026, an estimated $88.2K.
  • KLP Kapitalforvaltning first reported a position in Akebia Therapeutics in Q3 2025 and held it in 2 quarters.
  • KLP Kapitalforvaltning's Akebia Therapeutics position peaked at $150K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q1 2026, filed 29 Apr 2026.